Virtu KCG Holdings LLC bought a new position in shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 75,610 shares of the specialty pharmaceutical company’s stock, valued at approximately $832,000. Virtu KCG Holdings LLC owned 0.15% of SciClone Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Renaissance Technologies LLC lifted its holdings in shares of SciClone Pharmaceuticals by 21.9% during the second quarter. Renaissance Technologies LLC now owns 2,540,200 shares of the specialty pharmaceutical company’s stock worth $27,942,000 after purchasing an additional 456,100 shares during the period. Stonepine Capital Management LLC grew its position in SciClone Pharmaceuticals by 33.1% in the 1st quarter. Stonepine Capital Management LLC now owns 1,663,281 shares of the specialty pharmaceutical company’s stock valued at $16,300,000 after buying an additional 414,081 shares during the last quarter. GAM Holding AG acquired a new position in SciClone Pharmaceuticals in the 2nd quarter valued at $4,261,000. Athos Capital Ltd acquired a new position in SciClone Pharmaceuticals in the 2nd quarter valued at $3,126,000. Finally, Vanguard Group Inc. increased its stake in SciClone Pharmaceuticals by 9.2% in the 1st quarter. Vanguard Group Inc. now owns 2,948,846 shares of the specialty pharmaceutical company’s stock valued at $28,899,000 after buying an additional 248,785 shares during the period. Institutional investors and hedge funds own 72.86% of the company’s stock.

In other SciClone Pharmaceuticals news, VP Lan Xie sold 10,000 shares of the company’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total value of $110,000.00. Following the completion of the transaction, the vice president now owns 10,000 shares in the company, valued at approximately $110,000. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Hong Zhao sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total transaction of $330,000.00. Following the completion of the sale, the chief executive officer now owns 30,000 shares in the company, valued at approximately $330,000. The disclosure for this sale can be found here. Company insiders own 5.16% of the company’s stock.

SciClone Pharmaceuticals, Inc. (SCLN) opened at 11.125 on Wednesday. The firm has a market capitalization of $580.62 million, a price-to-earnings ratio of 13.718 and a beta of 1.72. The stock’s 50 day moving average is $11.08 and its 200-day moving average is $10.47. SciClone Pharmaceuticals, Inc. has a 52 week low of $8.55 and a 52 week high of $11.43.

SciClone Pharmaceuticals (NASDAQ:SCLN) last issued its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 EPS for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.02. SciClone Pharmaceuticals had a return on equity of 21.10% and a net margin of 25.18%. The firm had revenue of $44.52 million during the quarter. On average, equities research analysts expect that SciClone Pharmaceuticals, Inc. will post $0.94 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Virtu KCG Holdings LLC Buys New Holdings in SciClone Pharmaceuticals, Inc. (SCLN)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/04/virtu-kcg-holdings-llc-buys-new-holdings-in-sciclone-pharmaceuticals-inc-scln.html.

Separately, Maxim Group restated a “hold” rating on shares of SciClone Pharmaceuticals in a research report on Thursday, June 8th.

SciClone Pharmaceuticals Company Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Stock Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.